Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,…
Free online course from KnowledgeActionChange introduces new approaches in fight against smoking-related death and disease
LONDON, March 10, 2025 /PRNewswire/ -- UK-based public health agency, Knowledge•Action•Change (K•A•C), is launching…
ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen
LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical…
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
March 01, 2025 12:45 ET | Source: Celldex Therapeutics, Inc. - Greatly…
NYSE CONTENT ADVISORY: PRE-MARKET UPDATE + RARE DISEASE DAY AWARENESS
NEW YORK, Feb. 28, 2025 /PRNewswire/ -- The New York Stock Exchange…
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohns disease
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and…
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET…
Egetis Therapeutics to Feature MCT8 Deficiency on Behind the Mystery Airing on Lifetime in Honor of Rare Disease Day
STOCKHOLM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Egetis Therapeutics AB (publ) (“Egetis”…
Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring
The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular…
Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring
The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular…